Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at Jefferies 2019 Healthcare Conference in London
LYON, France and Cambridge, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen , Chief
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committee opened for patient enrollment in the United States first U.S.
View HTML
Toggle Summary ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Nov 20 - Nov 21, 2019

Jefferies Health Care Conference, London

Summary Toggle Nov 22, 2019

Actionaria, Paris

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top